Condition (MeSH)
Dermatomyositis
ClinicalTrials.gov lists 180 trials for Dermatomyositis or a narrower condition beneath it. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
180 of the 180 trials are tagged with Dermatomyositis itself; the rest are tagged with a narrower condition beneath it.
When did Dermatomyositis trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 19
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 19 |
| 2024 | 17 |
| 2023 | 14 |
| 2022 | 13 |
| 2021 | 12 |
| 2020 | 6 |
| 2019 | 6 |
| 2018 | 8 |
| 2017 | 8 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 28 trials still running at the 2026-10-09 snapshot; registered median of 32 months across 81 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dermatomyositis trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 26 |
| Phase 1/2 | 7 |
| Phase 2 | 40 |
| Phase 2/3 | 14 |
| Phase 3 | 16 |
| Phase 4 | 9 |
| Not applicable | 22 |
| Observational | 45 |
| Expanded access | 1 |
How many Dermatomyositis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 47 |
| Enrolling by invitation | 5 |
| Active, not recruiting | 8 |
| Completed | 75 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dermatomyositis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 8 |
| National Institute of Environmental Health Sciences (NIEHS) | 6 |
| Chongqing Precision Biotech Co., Ltd | 4 |
| Pfizer | 4 |
| Novartis Pharmaceuticals | 3 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Dermatomyositis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 3 |
| (CP-6890,550) Tofacitinib | 3 |
| Cytoxan | 3 |
| INFLIXIMAB | 3 |
| Sodium Thiosulfate | 3 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Baritinib | 4 |
| tocilizumab SC | 4 |
| Abatacept SC | 4 |
| Globulin, Immune | 3 |
| IR Tacrolimus | 3 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dermatomyositis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 11 | 4 |
| Cellulitis | 8 | 4 |
| Surgical Procedure | 8 | 1 |
| Polymyositis | 7 | 2 |
| COVID-19 | 6 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Dermatomyositis? (176)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients. | Rheumatology (Oxford, England) | 2025 | Yes |
| Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. | Lancet (London, England) | 2025 | Yes |
| Tofacitinib treatment for active dermatomyositis and anti-synthetase syndrome: a prospective cohort pilot study. | Rheumatology (Oxford, England) | 2025 | Yes |
| Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. | Rheumatology (Oxford, England) | 2025 | Yes |
| Diverse Lenabasum pathway activation in dermatomyositis patients' blood. | Scientific reports | 2025 | Yes |
Showing 5 of 176 publications.
Prevalence (42)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Dermatomyositis | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Dermatomyositis | Point prevalence | 1-5 / 10 000 | United States | US | Unspecified |
| Dermatomyositis | Point prevalence | 1-5 / 10 000 | United States | US | Exact |
| Dermatomyositis | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Dermatomyositis | Annual incidence | 1-9 / 100 000 | United States | US | Unspecified |
Showing 5 of 42 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Dermatomyositis | 221 | Exact | Orphadata Science knowledge files, Product 1 |
| Dermatomyositis | 221 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.